Brief: Hanall Biopharma Says Top-Line Data From Tanfanercept's Phase 3 Expected In H1 2023
01/02/2023 12:13
Feb 1 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA REPORTS FULL-YEAR 2022 RESULTS AND
PROVIDES
BUSINESS UPDATE
* HANALL BIOPHARMA CO LTD - TOP-LINE DATA FROM
TANFANERCEPT'S
PHASE 3 DRY EYE STUDY EXPECTED IN H1 2023
* HANALL BIOPHARMA CO LTD - CONTINUING WITH PRE-CLINICAL
DEVELOPMENT OF HL187 AND IS PREPARING FOR IND SUBMISSION IN 2023
Source text for Eikon: ID:nPn1pwVgba
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies